Latest News of APOG
Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
By Yahoo! Finance |
1 week ago
Apogee had $753.8 million in cash and securities as of September 30, 2024, ensuring funding for operations until Q1 2028....
Is Apogee Enterprises, Inc. (NASDAQ:APOG) Potentially Undervalued?
By Yahoo! Finance |
2 weeks ago
Apogee Enterprises, Inc. (NASDAQ:APOG) has seen a 24% rise in share price on NASDAQGS. Despite being overvalued by 31% based on DCF valuation, its low beta suggests a stable price....
Do You Believe in the Growth Prospects of Apogee (APOG)?
By Yahoo! Finance |
1 month ago
Middle Coast Investing's Q3 2024 investor letter discusses the portfolio performance, highlighting Apogee Enterprises, Inc. as a top pick. Apogee's stock showed significant growth and potential, empha...
-
Apogee Enterprises Joins Rank Of Stocks With RS Ratings Over 90
By Investor's Business Daily | 1 month agoLearn how market breadth indicators like IBD's RS Rating can reveal underlying weaknesses in a bull market. Find out how to interpret stock charts for profitable decisions and why Relative Strength Li...
-
Apogee Enterprises Inc (APOG) Q2 2025 Earnings Call Transcript Highlights: Navigating Revenue ...
By Yahoo! Finance | 1 month agoThe company expects full-year capital expenditures of $40-50 million. The acquisition of UW Solutions presents cross-selling opportunities in HD printable materials and industrial flooring. UW Solutio...
-
Apogee Enterprises, Inc.'s (NASDAQ:APOG) Intrinsic Value Is Potentially 22% Below Its Share Price
By Yahoo! Finance | 2 months agoThis article discusses estimating the intrinsic value of Apogee Enterprises, Inc. using the Discounted Cash Flow (DCF) model. It explains the steps involved in calculating future cash flows and highli...
-
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
By Yahoo! Finance | 2 months agoJane Henderson, CFO of Apogee Therapeutics Inc, sold 6,000 shares at $48.26 each on August 23, 2024. The company focuses on developing therapies for diseases with unmet medical needs. Henderson now ho...
-
Stocks Showing Rising Market Leadership: Apogee Enterprises Earns 82 RS Rating
By Investor's Business Daily | 3 months agoLearn how to find the best IPO stocks with a proprietary rating system that measures market leadership. Focus on stocks with an RS Rating above 80 for potential gains. Consider factors like earnings g...
-
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 3 months agoApogee Therapeutics, Inc. is a biotechnology company focusing on developing biologics for conditions like atopic dermatitis, asthma, and COPD. Their primary products are extended half-life monoclonal ...
-
Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE)
By Yahoo! Finance | 3 months agoApogee Therapeutics Inc focuses on developing innovative treatments for medical conditions. An insider recently sold shares worth $298,464.45, adding to a trend of insider selling. Investors should co...
-
Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares
By Yahoo! Finance | 3 months agoApogee Therapeutics Inc CEO, Michael Henderson, sold 40,000 shares at $40.62 each, totaling $1.62 million. With 1,434,487 shares left, the company focuses on innovative therapies....
-
Apogee Enterprises Earns Relative Strength Rating Upgrade; Hits Key Benchmark
By Investor's Business Daily | 4 months agoLearn how to identify game-changing stocks with a unique rating system that ranks stock price performance. Focus on factors like revenue growth, earnings, and industry ranking to hone your stock-picki...
-
Apogee Enterprises (NASDAQ:APOG) shareholders YoY returns are lagging the company's 21% three-year earnings growth
By Yahoo! Finance | 4 months agoInvesting in individual stocks like Apogee Enterprises can lead to higher returns compared to index funds. Despite recent stock price fluctuations, the company has shown strong earnings growth. Monito...
-
Apogee Therapeutics Shows Market Leadership With Jump To 92 RS Rating
By Investor's Business Daily | 4 months agoIBD identifies the Magnificent Seven stocks with a proprietary rating from 1 to 99, indicating price movement compared to other stocks. High RS Rating stocks often lead to significant gains. Apogee Th...
-
Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE)
By Yahoo! Finance | 4 months agoOn July 5, 2024, Apogee Therapeutics Inc's CEO sold 15,000 shares, now owning 1,474,487 shares. The company focuses on autoimmune disease treatments. Valued at $2.143 billion, recent insider transacti...